Why did THCT stock fall so sharply on 06 Mar 2026?

The fall reflects extremely low liquidity, a prior close of **$0.0180**, and market skepticism despite a recent 10-K filing and acquisition announcements. Thin volume and Expert Market status amplified selling pressure.

What is Meyka AI’s rating for THCT stock?

Meyka AI rates THCT **64.96 out of 100**, Grade **B**, Suggestion **HOLD**. The score factors benchmark comparisons, sector and industry metrics, financials, forecasts, and analyst signals.

What are the main financial risks for THCT stock?

Primary risks are very low cash per share, negative book value per share, a current ratio near **0.00030**, high debt-to-assets **60.93%**, and dilution risk from a small market cap and limited liquidity.

How should investors trade THCT stock now?

Use strict risk controls. Limit position size, use limit orders, avoid margin, and wait for clear SEC filings and improved volume before increasing exposure.

US Stocks

THCT (THC Therapeutics, Inc., PNK) drops to $0.0002 on 06 Mar 2026: key risk signals

ByDanny Kontos March 6, 2026March 6, 2026

THCT stock plunged to $0.0002 on 06 Mar 2026 during market hours, a -98.89% one-day swing from the prior close of $0.0180. That collapse left trading extremely thin with volume 1,000 shares and a market cap of $7,773.00 on the PNK exchange in the United States, USD. Investors should treat moves like this as liquidity-driven and news-sensitive. We examine drivers, financials, technicals, and Meyka AI model forecasts for THC Therapeutics, Inc. to highlight practical watch points and risk controls.